Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic fac...

Full description

Bibliographic Details
Main Authors: Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satoshi Hishiki, Shuhei Nishigori, Manabu Morimoto, Nobuhiro Hattori, Katsuaki Ogushi, Akito Nozaki, Hiroyuki Fukuda, Tatehiro Kagawa, Kojiro Michitaka, Takashi Kumada, Shin Maeda
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
hepatocellular carcinoma
lenvatinib
vascular endothelial growth factor
fibroblast growth factor 19
angiopoietin-2
biomarker
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/2072-6694/12/2/293

Similar Items

Similar Items